Synergistic antibacterial activity of chitosan-polyethylene glycol nanocomposites films containing ZIF-8 and doxycycline.
| Title: | Synergistic antibacterial activity of chitosan-polyethylene glycol nanocomposites films containing ZIF-8 and doxycycline. |
|---|---|
| Authors: | Jamiri F; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.; Nayeri Fasaei B; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. nayerib@ut.ac.ir.; Joghataei SM; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.; Yahyaraeyat R; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.; Mazloom-Jalali A; Department of Chemistry, Amir Kabir University of Technology (Tehran Polytechnic), P.O.Box: 15875-4413, Tehran, Iran. |
| Source: | BMC biotechnology [BMC Biotechnol] 2025 Feb 20; Vol. 25 (1), pp. 19. Date of Electronic Publication: 2025 Feb 20. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101088663 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6750 (Electronic) Linking ISSN: 14726750 NLM ISO Abbreviation: BMC Biotechnol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BioMed Central, 2001- |
| MeSH Terms: | Chitosan*/chemistry ; Chitosan*/pharmacology ; Doxycycline*/pharmacology ; Doxycycline*/chemistry ; Anti-Bacterial Agents*/pharmacology ; Anti-Bacterial Agents*/chemistry ; Polyethylene Glycols*/chemistry ; Polyethylene Glycols*/pharmacology ; Nanocomposites*/chemistry ; Metal-Organic Frameworks*/chemistry ; Metal-Organic Frameworks*/pharmacology ; Zeolites*/chemistry; Escherichia coli/drug effects ; Staphylococcus aureus/drug effects ; Microbial Sensitivity Tests ; Drug Liberation ; Drug Synergism ; Imidazoles |
| Abstract: | Background: Antibiotic resistance is a growing global threat due to antibiotic overuse and limited treatment options. Multidrug-resistant bacteria, like Staphylococcus aureus and Escherichia coli, increase infection complexity and mortality. This study explores nanocomposite films of ZIF-8 nanoparticles and Doxycycline (Dox) to enhance antibacterial efficacy. In this study, nanocomposite films composed of chitosan (CS) and polyethylene glycol (PEG), incorporating zeolitic imidazolate framework-8 (ZIF-8) nanoparticles and DOX, were developed. These films were characterized by their morphological, mechanical, antibacterial, and drug-release properties. Antibacterial efficacy was evaluated using disk diffusion, broth microdilution, and checkerboard assay methods to determine MICs and potential synergistic effects.; Results: The nanocomposite films demonstrated flexibility, semi-transparency, and a yellowish-brown hue, with films containing ZIF-8 nanoparticles being thicker (79 ± 0.2 μm) than those without (54 ± 0.5 μm). The tensile strength was enhanced with the incorporation of ZIF-8, peaking at 53.12 MPa for the CS-PEG-G-10% DOX-4% ZIF-8 film. XRD analysis confirmed the crystallinity of the ZIF-8 and DOX, with distinct peaks observed for each material. The drug release studies revealed an initial burst followed by sustained release, with higher release rates in acidic environments compared to neutral and alkaline media. The CS-PEG-G-10% DOX-4% ZIF-8 nanocomposite film demonstrated significantly higher antibacterial activity, achieving the lowest MIC values, particularly against S. aureus (22.5 mm inhibition zone) compared to E. coli (14 mm inhibition zone). Additionally, a notable synergistic effect was observed between CS-PEG-G-10% DOX and CS-PEG-G-10% DOX, with FICI values below 0.5.; Conclusions: The CS-PEG-G-10% DOX-4% ZIF-8 nanocomposite exhibits enhanced antibacterial efficacy and optimal properties, positioning it as a strong candidate for developing effective treatments against multidrug-resistant pathogens.; (© 2025. The Author(s).) |
| Competing Interests: | Declarations. Ethics approval and consent to participate: Not applicable. This article does not include any studies conducted by the authors involving human participants or animals. All research and analyses presented are based on experimental methods and data that do not include human or animal subjects. This disclaimer ensures compliance with ethical standards and regulations regarding research involving human and animal participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. |
| References: | J Control Release. 2022 Feb;342:53-65. (PMID: 34971694); Sci Rep. 2019 Nov 25;9(1):17439. (PMID: 31767932); J Chem Phys. 2023 Apr 14;158(14):144901. (PMID: 37061469); Nanoscale. 2024 Feb 29;16(9):4434-4483. (PMID: 38305732); Int J Mol Sci. 2023 Jun 23;24(13):. (PMID: 37445718); Glob Chall. 2023 Dec 30;8(2):2300244. (PMID: 38356684); Crit Rev Microbiol. 2016 Sep;42(5):696-719. (PMID: 26089024); Braz J Biol. 2023 Jan 30;84:e264946. (PMID: 36722677); Antibiotics (Basel). 2021 Apr 07;10(4):. (PMID: 33917043); Front Bioeng Biotechnol. 2024 Apr 09;12:1386534. (PMID: 38655386); Biomed Res Int. 2023 Feb 4;2023:2848198. (PMID: 36785668); Acta Pharm Sin B. 2019 Nov;9(6):1145-1162. (PMID: 31867161); Front Microbiol. 2018 Jul 02;9:1441. (PMID: 30013539); Int J Biol Macromol. 2016 Oct;91:778-88. (PMID: 27311504); J Colloid Interface Sci. 2017 Sep 1;501:60-76. (PMID: 28433886); IDCases. 2020 Jun 06;21:e00864. (PMID: 32566483); Molecules. 2019 Aug 22;24(17):. (PMID: 31443467); Pharmaceutics. 2023 Apr 19;15(4):. (PMID: 37111770); Int Microbiol. 2019 Jun;22(2):239-246. (PMID: 30810990); Nanomicro Lett. 2015;7(3):219-242. (PMID: 30464967); Int J Pharm. 2022 Apr 25;618:121655. (PMID: 35283220); Chemosphere. 2023 Oct;339:139713. (PMID: 37549744); Cell Biochem Biophys. 2024 Dec;82(4):3071-3090. (PMID: 39023679); Int J Nanomedicine. 2024 Jun 10;19:5523-5544. (PMID: 38882544); Br J Biomed Sci. 2023 Jun 28;80:11387. (PMID: 37448857); ACS Omega. 2023 Dec 12;8(51):49244-49258. (PMID: 38162750); Colloids Surf B Biointerfaces. 2019 Oct 1;182:110364. (PMID: 31352254); Eur J Pharm Sci. 2024 Apr 1;195:106636. (PMID: 38185273); J Pharm Sci. 2019 Sep;108(9):3046-3053. (PMID: 31091425); Biomedicines. 2023 Oct 18;11(10):. (PMID: 37893205); J Mater Chem B. 2019 Oct 16;7(40):6156-6171. (PMID: 31559403); RSC Adv. 2024 Feb 13;14(8):5601-5608. (PMID: 38352679); Pharmaceutics. 2023 Jan 11;15(1):. (PMID: 36678888); Int J Biol Macromol. 2019 Jun 1;130:727-736. (PMID: 30771392); Int J Biol Macromol. 2019 Dec 1;141:936-946. (PMID: 31487516); J Drug Target. 2019 Apr;27(4):379-393. (PMID: 30103626); Biofabrication. 2024 Aug 29;16(4):. (PMID: 39102846); Int J Pharm. 2024 Mar 5;652:123821. (PMID: 38242259); Biomater Sci. 2024 Sep 10;12(18):4630-4649. (PMID: 39140167); Int J Biol Macromol. 2020 Jun 15;153:421-432. (PMID: 32151721); J Colloid Interface Sci. 2024 Dec;675:1040-1051. (PMID: 39008922); J Mater Sci Mater Med. 2019 Apr 22;30(5):51. (PMID: 31011810); J Biomater Appl. 2019 May;33(10):1327-1347. (PMID: 30880549); Curr Microbiol. 2020 Sep;77(9):2287-2299. (PMID: 32535649); BMC Microbiol. 2024 Jul 9;24(1):254. (PMID: 38982372); J Antibiot (Tokyo). 2023 May;76(5):291-300. (PMID: 36854977); Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:109930. (PMID: 31500069); Eur J Pharm Sci. 2019 Jan 15;127:121-141. (PMID: 30342173); BMC Vet Res. 2024 Apr 1;20(1):130. (PMID: 38561827); Carbohydr Polym. 2018 Dec 1;201:522-531. (PMID: 30241849); Pharmaceutics. 2023 Jul 09;15(7):. (PMID: 37514100); Mol Pharm. 2023 Mar 6;20(3):1490-1499. (PMID: 36490379); Heliyon. 2023 Jun 24;9(6):e17488. (PMID: 37416680) |
| Contributed Indexing: | Keywords: Escherichia coli; Staphylococcus aureus; Antibacterial drugs; Chitosan; Doxycycline; Drug delivery; Metal-organic frameworks; Nanocomposites; ZIF-8 nanoparticle |
| Substance Nomenclature: | 9012-76-4 (Chitosan); N12000U13O (Doxycycline); 0 (Anti-Bacterial Agents); 3WJQ0SDW1A (Polyethylene Glycols); 0 (Metal-Organic Frameworks); 1318-02-1 (Zeolites); 0 (ZIF-8 metal-organic framework); 0 (Imidazoles) |
| Entry Date(s): | Date Created: 20250220 Date Completed: 20250508 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11841006 |
| DOI: | 10.1186/s12896-025-00953-x |
| PMID: | 39979993 |
| Database: | MEDLINE |
Journal Article